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Mounting evidence suggests that the guanine-based purines stand out as key player
in cell metabolism and in several models of neurodegenerative disorders, such as
Parkinson’s and Alzheimer’s diseases. Guanosine (GUO) and guanine (GUA) are
extracellular signaling molecules derived from the breakdown of the correspondent
nucleotide, GTP, and their intracellular and extracellular levels are regulated by the
fine-tuned activity of two major enzymes, purine nucleoside phosphorylase (PNP) and
guanine deaminase (GDA). Noteworthy, GUO and GUA, seem to play opposite roles
in the modulation of cognitive functions, such as learning and memory. Indeed GUO,
despite exerting neuroprotective, anti-apoptotic and neurotrophic effects, causes a
decay of cognitive activities, whereas GUA administration in rats results in working
memory improvement (prevented by L-NAME pre-treatment). This study was designed
to investigate, in a model of SH-SY5Y neuroblastoma cell line, the signal transduction
pathway activated by extracellular GUA. Altogether, our results showed that: (i) in
addition to an enhanced phosphorylation of ASK1, p38 and JNK, likely linked to
a non-massive and transient ROS production, the PKB/NO/sGC/cGMP/PKG/ERK
cascade seems to be the main signaling pathway elicited by extracellular GUA; (ii) the
activation of this pathway occurs in a pertussis-toxin sensitive manner, thus suggesting
the involvement of a putative G protein coupled receptor; (iii) the GUA-induced
NO production, strongly reduced by cell pre-treatment with L-NAME, is negatively
modulated by the EPAC-cAMP-CaMKII pathway, which causes the over-expression of
GDA that, in turn, reduces the levels of GUA. These molecular mechanisms activated
by GUA may be useful to support our previous observation showing that GUA improves
learning and memory functions through the stimulation of NO signaling pathway, and
underscore the therapeutic potential of oral administration of guanine for treating
memory-related disorders.
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INTRODUCTION
Guanine-based purines are known to play crucial role in
the modulation of neurotransmission and neuropathologies
(Ciccarelli et al., 2001; Boison, 2011; Bettio et al., 2016; Di
Liberto et al., 2016). In particular, the purine nucleoside
Guanosine (GUO), which is mostly released from astrocytes
under pathological conditions (i.e., hypoxic or hypoglycemic
stress), is thought to exert both neurotrophic and neuroprotective
effects (Di Iorio et al., 2001, 2004; Giuliani et al., 2012, 2015;
Lanznaster et al., 2016); indeed, it oversees neuronal development
and synaptic activity, and protects neuronal and glial cells against
oxidative stress and excitotoxicity (Neary, 1996; Schmidt et al.,
2007; Tarozzi et al., 2010; Quincozes-Santos et al., 2014; Bellaver
et al., 2015; Ribeiro, 2016; Thomaz et al., 2016). Furthermore, in
rats, GUO administration during pre-training displays amnesic
effect on inhibitory avoidance task (Roesler et al., 2000; Vinadé
et al., 2004; Saute et al., 2006). At present, much less is known
about the effects that Guanine (GUA) exerts in the central
nervous system. Intracellular GUA derives from guanosine
triphosphate (GTP) breakdown and represents the starting point
of reactions deputed to maintain intracellular levels of GTP
(purine salvage pathway). When intracellular levels of GUA are
excessive, it may be transported outside the cells by specific
transmembrane nucleobases transporters, although most of the
extracellular GUA derives from the breakdown of the released
GTP and it is generated by GUO in a reaction catalyzed by the
purine nucleoside phosphorylase (PNP) (Rathbone et al., 2008;
Giuliani et al., 2016, 2017; Peña-Altamira et al., 2017). On the
contrary, GUA degradation to xanthine (Xan) is mediated by
Guanine deaminase (GDA) or cypin (Miyamoto et al., 1982),
which has been regarded as one of the “intrinsic factors” that
regulate dendrite morphology together with the small GTPases
RhoA, Rac1, the β-catenin (Yu and Malenka, 2004), PSD-95
(Charych et al., 2006) and the calcium/calmodulin-dependent
protein kinase II (CAMKII) (Fink et al., 2003). CaMKII is a
synaptic signaling molecule that plays a crucial role during
long-term memory formation (Lucchesi et al., 2011) and its
endogenous inhibitors CaMK2N1 and CaMK2N2 are highly
expressed during memory consolidation (Lepicard et al., 2006).
Cyclic AMP-CREB axis is implicated in learning and memory
processes and has been shown to activate CaMKII.
In a previous work (Giuliani et al., 2012), we reported
the effects of GUO and GUA on learning and memory in
a model of passive avoidance task in rats. In that study,
the oral administration of GUO exerted amnesic activity on
inhibitory avoidance task and was unable to prevent the
amnesic effect caused by N-omega-nitro-l-arginine methyl ester
(L-NAME), a non-specific NOS inhibitor known to reduce the
capability of treated animals to acquire or retain information
in several learning tasks. Conversely, the administration of
GUA counteracted the L-NAME-mediated amnesic effects, by
increasing the step-through latency either when it was given in
the learning phase or during the memory consolidation phase.
In addition to GUO and GUA, another guanine-based
purine has been correlated to changes in memory processes,
namely cyclic guanosine monophosphate (cGMP), which exerts
memory-enhancing effect through the modulation of NMDA
receptors and the glutamate-nitric oxide (NO) pathway (Cabrera-
Pastor et al., 2016) or via NOS-soluble guanylyl cyclase (sGC)-
cGMP- protein kinase G (PKG) pathway (Friebe and Koesling,
2003; Boess et al., 2004; Masood et al., 2009; Bollen et al., 2014;
Lueptow et al., 2015). Noteworthy, there is a large body of
evidence confirming the existence of a cross-talk between NO and
ERK signaling pathways during memory formation and learning
processes (Moosavi et al., 2014). Indeed, it has been shown that
ERK represents a crucial downstream mediator of NO in the
brain (Chien et al., 2008) and that the blockage of NO-cGMP-
PKG prevents the activation of ERK mediated by high-frequency
stimulation-(HFS) (Ping and Schafe, 2010).
Based on the above mentioned mnesic effects elicited, in vivo,
by GUA, and several findings showing that NO-cGMP-PKG-ERK
signaling pathway is positively correlated with enhancement of
memory formation (Adams and Sweatt, 2002; Davis and Laroche,
2006; Giovannini, 2006; Philips et al., 2007; Chien et al., 2008;
Adaikkan and Rosenblum, 2012), in this study we aimed to:
(a) verify, by using human neuroblastoma cell line SH-SY5Y,
if cGMP and NO-PKG-ERK signaling pathway resulted to
be activated upon cell exposure to GUA;
(b) assess whether the activation of this signaling pathway




The human neuroblastoma cell line SH-SY5Y was
purchased from European Collection of Authenticated Cell
Culture (ECACC, Salisbury, United Kingdom); Guanine,
Guanosine, Nutrient Mixture F-12 Ham, Minimum Essential
Medium Eagle (MEM), Non-Essential Amino Acids (NEAA),
L-Glutamine, Trypsin-EDTA, Pertussis toxin from Bordetella
pertussis (PTX), 3-Isobutyl-1-methylxanthine (IBMX), -˝[1,2,4]
Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 8-(4-Chloro-
phenylthio)-2′-O-methyladenosine 3′,5′-cyclic monophosphate
monosodium hydrate (8-pCPT-2′-O-Me-cAMP), N-[2-[N-(4-
Chlorocinnamyl)-N-methylaminomethyl]phenyl]-N-(2-hydrox
yethyl)-4-methoxybenzenesulfonamide phosphate salt, N-[2-[[
[3-(4′-Chlorophenyl)-2-propenyl]methylamino]methyl]phenyl]-
N-(2-hydroxyethyl)-4′-methoxybenzenesulfonamide phosphate
salt (KN-93), Propentofylline, S-(4-Nitrobenzyl)-6-thioinosine
(NBTI), 2′,7′-Dichlorofluorescin diacetate (H2DCF-DA),
dimethylsulfoxide (DMSO), Ionomycin, trypsin/EDTA, EDTA,
EGTA, HEPES, Phosphate Buffer Solution (PBS), dithiothreitol
(DTT), NADPH, calmodulin, CaCl2, tetrahydrobiopterin
and the cationic exchange resin Dowex AG50WX-8, N-(1-
naphthylethylenediamine) dihydrochloride, were purchased
from Sigma (Milan, Italy); NG-Nitro-L-arginine methyl ester
hydrochloride (L-NAME), MSC 20329644, GF109203X,
10-DEBC hydrochloride, Dipyridamole and LY 294002
hydrochloride were purchased from Tocris (Milan, Italy);
Penicillin-streptomycin and Heat-inactivated fetal bovine
Frontiers in Pharmacology | www.frontiersin.org 2 February 2018 | Volume 9 | Article 110
fphar-09-00110 February 21, 2018 Time: 12:20 # 3
Zuccarini et al. Guanine Signaling behind Activation of NO
serum (FBS) were purchased from Gibco R© (Thermo Fischer
Scientific, Monza, Italy); Phospho-ASK1, Phospho-p38 MAPK,
Phospho-SAPK/JNK, Phospho-PKC (pan), Phospho-Akt,
Phospho-p44/42 MAPK (Erk1/2), β-Actin, secondary anti-rabbit
IgG HRP-linked antibody were purchased from Cell Signaling
Technology (Cell Signaling, Leiden, Netherlands); PNP and
Guanase Deaminase antibodies were purchased from Novus
Biologicals (Space Import-Export, Milan, Italy).
Cell Culture
The human neuroblastoma cells, SH-SY5Y, were cultured in
75 cm2 flasks in a 1:1 mixture of F-12 nutrient mixture (Ham 12)
and Eagle’s MEM (EBSS) supplemented with 2 mM Glutamine,
1% Non-Essential Amino Acids (NEAA), 15% Foetal Bovine
Serum (FBS) and 100 units/mL penicillin and 100 µg/mL
streptomycin and maintained at 37◦C in 5% CO2, humified air.
For the evaluation of PNP and GDA release, cell medium was
removed and replaced by serum free-medium and maintained
in humified atmosphere, 5% CO2, 37◦C. At the end of the
experiment, aliquots (2 mL) of the culture medium were
collected, placed in suitable devices (Amikon Ultra 2 mL, cutoff
10 K, Merck Millipore, Germany) and centrifuged following the
manufacturer’s instruction, in order to concentrate culture media
containing the enzymes.
For the evaluation of purine release, cell medium was removed
and replaced with Krebs-HEPES buffer (15 m M HEPES, pH
7.4, 120 mM NaCl, 4 mM KCl, 1.2 mM MgSO4, 1 mM
CaCl2), and 10 mM D-glucose oxygenated (95% O2/5% CO2).
After 30 min, the cells were incubated for further 30 min
with the same buffer containing 2.5 µM GUO combined
with 0.675 µM of [3H]GUO (specific activity 5.3 Ci/mmol;
Movarek Biochemicals). At the end of this incubation period,
cells were washed twice with unlabeled Krebs-HEPES buffer
and maintained in this medium in standard condition (37◦C,
5% CO2). When used, purine uptake inhibitors were added to
Krebs-HEPES just after the incubation with labeled GUO. At
the end of the experiment, an aliquot of the culture medium
was collected and immediately heat-inactivated for 5 min at
70◦C to avoid any further enzymatic degradation of the released
purine. Samples were, then, centrifuged, filtered with 0.2 µm




For Immunoblot assays, SH-SY5Y cells were subcultured
in 100 × 20-mm Petri Dishes (BD Falcon) at a seeding
density of 2 × 105 per dish (for each sample two dishes were
pulled together) and grown until 80% confluence. Before all
experiments, cells were starved for 24 h in medium containing
0.1% FBS.
HPLC Method for the Evaluation of
Purine Levels in the Extracellular Milieu
According to the method previously described (Giuliani et al.,
2012, 2017), purines were measured by an Agilent 1100
series HPLC system (Agilent Technologies, Santa Clara, CA,
United States), by using, for the separation of the compounds,
a reverse phase analytical column (LiChrospher 100 RP-18
5 µm in LiChroCART 125-4, Merck) and a 15-min linear
gradient [from 100% of buffer A (60 mM KH2PO4 and 5 mM
tetrabutylammonium phosphate, pH 6.0) to 100% solvent B (30%
methanol plus 70% buffer A)] at a flow rate of 1.5 mL/min.
The detection of unlabeled compounds was achieved using
a Diode Array Detector (Agilent Technologies, Santa Clara,
CA, United States) with wavelength set at 254 nm for all
the substances except Uric Acid (UAc), which was 290 nm.
Released purines were identified and quantified by comparison
with pure external standards. Since many purine compounds
are present in the extracellular milieu at concentrations below
the UV detection limit, the HPLC system was equipped with
an online radiochemical detector (FLO-ONE 500 TR, Packard
Instruments) for the concurrent measurement of radiolabeled
purine present in the outflow from the Diode Array Detector,
in order to improve the sensibility of the analysis. Thus,
the HPLC eﬄuent was mixed with the liquid scintillation
cocktail (Ultima-FloM, Perkin-Elmer) at a flow ratio of 2:1
and passed through a 500 µL detector flow cell. Radio-
chromatograms were integrated and each radioactive peak was
quantified.
Measurement of Enzyme Activity in the
Extracellular Milieu
PNP activity was measured in an assay buffer containing
50 mM HEPES, pH 7.0, 50 mM inorganic phosphate (Pi),
used as co-substrate, and 200 µM GUO used as substrate,
whereas the mixture used to evaluate GDA activity consisted of
100 mM TrisHCl pH 8 plus 200 µM GUA used as substrate.
These enzymatic reactions were started by adding aliquot of
the concentrated extracellular culture medium. The mixtures
were then incubated by shaking at 37◦C for 15 min, to
evaluate PNP activity, and for 60 min, to determine GDA
activity. The reactions were stopped by heating the mixture at
70◦C for 5 min and the precipitated proteins were removed
by centrifugation. The enzyme activity was determined by
quantifying the rate of conversion of GUO to GUA, for PNP, or
the conversion of GUA to XAN for GDA, using the HPLCmethod
previously described (Giuliani et al., 2016). In this case, the
Agilent HPLC was equipped with a thermostated column
compartment, a diode array detector, and a fluorescence detector
(Agilent Technologies). Briefly, separation was achieved using
a Phenomenex Kinetex pentafluorophenyl analytical column
(5 µm pore size, 100 Å particle size, 250× 4.6 mm; Phenomenex
INC) at 35◦C. Separation was carried out with a 15-min non-
linear gradient elution (flow rate 1 mL/min) using a mobile
phase composed of 0.1% (v/v) formic acid in water (solution A)
and methanol (solution B). The fluorescent GUO and GUA
were monitored at an excitation wavelength of 260 nm and an
emission wavelength of 375 nm, whereas for the non-fluorescent
compounds, i.e., XAN and UAc, the UV detector was set at
254 and 290 nm respectively. Allsubstances were identified and
quantified by comparison with pure external standards. Enzyme
activity was expressed as Unit (U) present in the total medium,
being 1 U of enzyme the amount of enzyme that converts 1µmole
of substrateinto product per min.
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Cell Viability Assay
Cell death was monitored by using the CytoTox-96 assay
(Promega Italia, Milan, Italy) that allows to evaluate the
lactate dehydrogenase (LDH) activity. The assay is based
on a 30-min coupled enzymatic assay, catalyzed by released
LDH, which results in conversion of a tetrazolium salt, 2-
p-(iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride
(INT), into a red formazan product. SH-SY5Y cells were seeded
in 96-well plates at 5 × 103 cells/well of confluence and
incubated for 2 days. For all samples, the cell culture medium
was replaced with Krebs-HEPES buffer (15 mM HEPES, pH
7.4, 120 mM NaCl, 4 mM KCl, 1.2 mM MgSO4, 1 mM
CaCl2) with or without 50 µM GUA (0–12 h). At the end
of exposure, the Lysis solution was added for 45 min to
control wells for the determination of maximum LDH release.
Afterward, 50 µL of collected media were transferred to a
fresh 96-well (enzymatic assay) plate, together with 50 µL
of Substrate buffer containing 0.7 mM p-iodonitrotetrazolium
Violet, 50 mM L-lactic acid, 0.3 mM phenazine methoxysulfate,
0.4 mM NAD and 0.2 M Tris-HCl pH 8.0. Finally, the plate
was protected from light and incubated for 30 min at RT.
The absorbance was recorded at 490 nm of wavelength in a
microplate reader after adding the Stop Solution. LDH activity
was expressed as the proportion of LDH released into the
culture medium compared to the total amount of LDH present
in cells lysates and calculated as follows: (medium absorbance
value – white absorbance value)/(medium absorbance + lysate
absorbance)× 100.
Immunoblot
SH-SY5Y cells were seeded overnight onto 100 mm Petri
Dishes (BD Falcon) at 2.0 × 105 cells/dish in 6 mL of 1:1
mixture of F-12 nutrient mixture (Ham 12) and Eagle’s MEM
(EBSS) supplemented with 2 mM Glutamine, 1% Non Essential
Amino Acids (NEAA), 15% Foetal Bovine Serum (FBS) and
100 units/mL penicillin and 100 µg/mL streptomycin. After 24-h
starvation, cells were submitted to different treatments in MEM
supplemented with 0.5% FBS and 1% Penicillin/Streptomycin.
After treatment, cells were washed twice with ice cold 1×
PBS (Sigma–Aldrich), lysed with RIPA Buffer (Sigma–Aldrich)
containing 150 mM NaCl, 10 mM EDTA, 1% NP40, 0.5%
deoxycholic acid, 0.1% SDS, and 50 mM Tris, pH 7.5,
supplemented with 1% Protease Inhibitor Cocktail (Sigma–
Aldrich), scraped off, pulled, and clarified by centrifugation at
12.500 × g for 20 min, 4◦C. Before performing Immunoblot, a
sample buffer (5× Laemmli buffer with 10% mercaptoethanol)
was added to melted lysates 1:4. Protein concentrations were
obtained using the Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, CA, United States) based on the Bradford method. An
equal amount of 50–70µg of protein was resolved by 10% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).
The resolved proteins were transferred onto a nitrocellulose
membrane and then incubated with blocking buffer 1× TBS
containing 0.1% Tween-20 (TBST) and 3% BSA or 5% non-
fat dry milk for 2 h, RT, and subsequently probed with specific
primary antibody at 4◦C, overnight. After washing with TBST, the
membrane was further probed with corresponding horseradish
peroxidase (HRP)-conjugated secondary antibodies at RT for
1 h. Membranes were finally washed, before subjecting them
to ECL Plus Immunoblot Detection Reagent (Amersham, GE
Healthcare). The immunoreactive bands were visualized under
a chemiluminescence detection system (UVItec, Cambridge,
United Kingdom). Band intensity data were obtained using
Quantity One software (Bio-Rad Laboratories). Blotting
membranes were stripped and re-probed with anti-actin
antibody as equal loading control. Estimates of phosphorylated
proteins are presented as densitometric ratios, normalized
to the corresponding total protein content. Apart from PNP
antibody (1:500), all primary antibodies [Phospho-ASK1 (Ser83),
Phospho-p38 MAPK (Thr180/Tyr182), Phospho-SAPK/JNK
(Thr183/Tyr185), Phospho-PKC (Ser660), Phospho-Akt
(Thr450), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204),
Guanase Deaminase, β-Actin] were diluted 1:1000 in 3% BSA/1×
TBS/0.1% Tween 20 or 2.5% non-fat dry milk/1× TBS/0.1%
Tween 20. The secondary antibody was used at 1:2500 dilution
in 3% BSA/1× TBS/0.1% Tween 20 or 2.5% non-fat dry milk/1×
TBS/0.1% Tween 20.
Measurement of Cellular Reactive
Oxygen Species (ROS)
The amount of intracellular reactive oxygen species (ROS) was
measured by using the probe H2DCF-DA (Ha et al., 1997),
which diffuses into the cells and is oxidized to the green
fluorescent compound 2′,7′-dichlorofluorescein (DCF) upon
reaction with intracellular hydrogen peroxide or low-molecular-
weight hydroperoxides. Cells were seeded at 1× 106 cells/well in
6-well culture plates and incubated overnight. After exposure to
different concentration of GUA for 30 min, cells were incubated
with 5 µM H2DCF-DA for 30 min, in the dark, at 37◦C.
At the end of incubation, the cells were washed with PBS
and fluorescence was measured at an excitation wavelength of
480 nm and an emission wavelength of 540 nm in a fluorescence
microplate reader (Thermo Fischer Scientific, Monza, Italy).
ROS production was determined by analyzing DCF fluorescence
normalized for total protein content. The fluorescence intensity
was proportional to the amount of ROS produced by cells.
Determination of Nitric Oxide
Synthase (NOS) Activity
Nitric oxide synthase activity was measured from the conversion
of L-[3 H]-arginine to L-[3 H]-citrulline based on the method
of Bredt et al. (1991) with modifications. SH-SY5Y cells were
grown overnight in 6-well plates. After 24-h starvation, cells
were exposed for 30 min to 50 µM GUA, 5 µM L-NAME or
2 µM Ionomycin, the latter used as positive control. When used
in combination, L-NAME was administered 15 min before cell
exposure to GUA or Ionomycin. Thereafter, cells were washed
three times with ice-cold 1X PBS, scraped in 1X PBS containing
1 mM EDTA, and centrifuged for 10 min at 1200 g. The pellets
were resuspended in a reaction buffer containing 50 mM Hepes,
1 mM EDTA, 1mM DTT (pH 7.2) and sonicated on ice with
two 10 s bursts. The reaction was started by addition to samples
of reaction mixture [1 mM NADPH, 1 nmol/l calmodulin,
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FIGURE 1 | SH-SY5Y neuroblastoma cells release guanine-based purines, PNP and GDA in the culture medium. (A) HPLC analysis of intracellular levels of
Guanine-based purines in SH-SY5Y cells. (B) HPLC analysis of extracellular levels of guanine-based purines at rest (control) and in the presence of the inhibitors of
cell uptake. SH-SY5Y were incubated with 2.5 µM guanosine (GUO) combined with 0.675 µM of [3H]GUO, the latter used as tracer. Values are expressed as
nmoles/mL of culture medium, and represent the mean ± SEM of five independent experiments. ∗p < 0.05; ∗∗p < 0.01: statistical significance versus untreated cells
(control) (Student’s t-test). (C) Evaluation of the presence and activity of purine nucleoside phosphorylase (PNP) and guanine deaminase (GDA) in the culture medium
of SH-SY5Y cells. (C1) Representative Immunoblots of PNP and GDA expression in SH-SY5Y culture medium. After 24 h incubation, SH-SY5Y cell culture medium
was collected after 3, 6, and 12 h, concentrated and analyzed for PNP and GDA expression. (C2) HPLC analysis of PNP and GDA activity evaluated up to 12 h. PNP
activity was assayed by using 200 µM guanosine (GUO) as substrate plus 50 mM Pi as co-substrate for 15 min at 37◦C, whereas GDA activity was measured by
using 100 mM TrisHCl pH 8 plus 200 µM GUA as substrate for 60 min at 37◦C. Values are expressed as milli-International Units (mIU) of enzyme per total culture
medium and represent the mean ± SEM of three independent experiments, run in duplicate. (C3) Evaluation of cell viability of SH-SY5Y cells by LDH assay. Values
are expressed as the percentage of the intracellular LDH activity that was determined after cell lysis, and represent the mean ± SEM of five different experiments.
1.25 mM CaCl2, 3 µM tetrahydrobiopterin, 2.5 µCi/µl of
L-[3H]arginine (Perkin Elmer, Boston, MA, United States,
specific activity 42.6 Ci/mmol), unlabelled arginine]. After an
incubation of 15 min at 37◦C, the assay was stopped by
adding 20 mM Hepes-Na containing 2 mM EDTA and 2 mM
EGTA (pH 5.5), and the reaction mixture was applied to
2-ml columns of Dowex AG50WX-8 (Na+ form), which were
eluted with 4 ml of water. The radioactivity corresponding
to the [3H]-citrulline was measured by liquid scintillation
analyzer (Tris-Carb 2100 TR, Perkin Elmer) and normalized
for extract protein content determined with Bradford method.
NOS activity was expressed as pmoles citrulline/min/mg cell
protein.
Statistical Analysis
Data are represented as means ± standard error of mean (SEM).
Comparisons among experimental groups were performed by
Student t-test or by two-way ANOVA followed by Sidak’s
multiple comparisons test using GraphPad Prism 6.01 (San
Diego, CA, United States), as indicated. Statistical difference was
accepted when P < 0.05. All experiments were performed at least
three times.
RESULTS
The Levels of Guanine-Based Purines in
SH-SY5Y Culture Media Are Controlled
by Specific Nucleobase and Nucleoside
Transporters and by the Presence of
Purine-Converting Enzymes
A hallmark of several neurodegenerative diseases is the activation
of neuronal and glial cells and the following induction of
oxidative stress and neuronal toxicity. In the attempt to
investigate neuronal response to GUA exposure, we used SH-
SY5Y, a human derived neuroblastoma cell, which has been
often used as a model to study molecular mechanisms associated
to ROS production, apoptosis and amyloid-β-induced neuronal
toxicity in Alzheimer’s disease (Tarozzi et al., 2010; Ali-Rahmani
et al., 2014; Puangmalai et al., 2017; Modi et al., 2017).
We firstly measured both the intracellular and extracellular
levels of purines in cultured SH-SY5Y cells, in resting conditions.
In the SH-SH5Y lysates, the levels of Guanine-based nucleotides
prevailed over the correspondent nucleobases and the inhibition
of the uptake, performed by treating cell culture with a cocktail
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FIGURE 2 | Guanine (GUA) induces ROS production in SH-SY5Y
neuroblastoma cells in a dose-dependent manner. (A) SH-SY5Y cells were
incubated for 30 min with different concentrations of GUA (0–100 µM). The
levels of ROS are presented as folds of control and represent the
mean ± SEM of five different experiments. (B) Evaluation of cell viability of
SH-SY5Y cells exposed to 50 µM GUA up to 4 h. Values are expressed as
the percentage of the intracellular LDH activity that was determined after cell
lysis and represent the mean ± SEM of five different experiments.
of inhibitors of nucleoside and nucleobase transmembrane
transporters (100 µM propentofylline, 10 µM NBTI, 10 µM
dypiridamole) did not caused any significant effect (Figure 1A).
An opposite trend was observed in the culture medium,
wherein the uptake inhibitors significantly increased extracellular
levels of GUA, Xan and UAc [two-way ANOVA analysis and
Sidak’s multiple comparisons test: P < 0,005] (Figure 1B).
This suggested that the levels of extracellular guanine-based
purines depended both on the balance between nucleotide
release and nucleoside uptake and on the presence, in the
culture medium, of extracellular purine-converting enzymes.
Indeed, by using Immunoblot analysis and HPLC for the
measurement of the enzyme activities (Giuliani et al., 2017),
we confirmed the presence in the culture medium of PNP and
GDA (Figure 1C). Both the enzymes tended to accumulate
in the culture medium over the time (from 2 up to 12 h)
following a similar trend even though at different levels (PNP
amount was about 7–10 fold higher than GDA). This event
was not associated with significant cell damage or death,
as demonstrated by the constant and minor presence of
LDH, measured during the same period in the culture media
(Figure 1C).
Guanine Increases ASK1, p38, JNK, PKC
and PKB Phosphorylation and This Effect
Is Prevented, Except for PKB, by Cell
Treatment with a Cocktail of Inhibitors of
the Uptake
Cell exposure to exogenous GUA, for 30 min, elicited a
non-massive and dose-dependent production of ROS. This
occurred without any significant collateral LDH production
(Figure 2). A similar effect has been found in different
glial cells (astrocytes or microglial cells, data not shown),
wherein ROS production seemed to be even greater than that
elicited in SH-SY5Y cells. The ROS production has been often
associated with an increased phosphorylation of ASK1, p38
and JNK (Shen and Liu, 2006; Jiang et al., 2017) and it has
been reported that the inhibition of c-Jun N-terminal Kinase
(JNK) in SH-SY5Y cells, prevented 6-Hydroxydopamine-induced
ROS production and toxicity (Feng et al., 2013). Based on
this evidence, we investigated which signaling transduction
pathways were involved in GUA-induced effect. SH-SY5Y cells
were exposed to 50 µM GUA, the half maximal effective
concentration, for 10 min, and the expression of p-ASK1,
p-p38, p-JNK, PKC and PKB was analyzed by Immunoblot.
The short-term exposure of cells to GUA significantly increased
the phosphorylation of all the mentioned kinases. The two-
way ANOVA analysis of their expression showed an effect
of cell exposure to GUA [F(1,12) = 27.53, P = 0.0002 for
p-ASK1; F(1,12) = 16.89, P = 0.0014 for p-38; F(1,12) = 41.35,
P = 0.0001 for p-JNK; F(1,12) = 16.09, P = 0.0017 for PKC
and F(1,12) = 27.07, P = 0.0002 for PKB] (Figures 3A,B).
Cell pre-treatment with the previously mentioned cocktail of
inhibitors of both nucleoside and nucleobase transmembrane
transporters, 30 min before cell exposure to GUA, did not
modify the basal phosphorylation level of all kinases but strongly
reduced GUA-induced phosphorylation of ASK1, p38, JNK
and PKC, [two-way ANOVA: F(1,12) = 4.77, P = 0.045 for
p-ASK1; F(1,12) = 13.07, P = 0.0035 for p-JNK; F(1,12) = 7.20,
P = 0.019 for PKC with interaction values between factors
of F(1,12) = 13.86, P = 0.0029; F(1,12) = 15.51, P = 0.002
and F(1,12) = 22.49, P = 0.0005, respectively], revealing that
the effect of GUA on these pathways was mainly intracellular
(Figures 3A,B). Conversely, GUA-induced phosphorylation of
PKB was not modified, [two-way ANOVA: F(1,12) = 0.6131,
P = 0.4488 and no effect of the interaction between both factors
F(1,12) = 0.01, P = 0.9212], thus suggesting that the activation of
this pathway mainly depends on the extracellular activity of GUA
(Figure 3C).
PI3K-PKB-ERK Is the Main Signaling
Pathway Activated by Extracellular GUA
in SH-SY5Y Cells
Due to the evidence that ERK stands out as a key player in
the modulation of several memory processes (Giovannini, 2006)
and that, in different experimental models, it represents the
downstream effector of ROS-induced phosphorylation of ASK1,
p38 and JNK (Lee and Cheong, 2017), we sought to determine
the relevance of each of these pathways on GUA-induced effect,
by selectively blocking ASK1 or PKC, two upstream kinases in
ERK signaling. Immunoblot analysis of p-ERK1/2 expression
revealed that GUA elicited a dose-dependent phosphorylation
of ERK (10-100 µM), [two-way ANOVA analysis and Sidak’s
multiple comparisons test: P < 0,005 for GUA 50 and
100 µM] and the time course [two-way ANOVA analysis:
F(1,24) = 74.57, P< 0,0001 with interaction values between factors
of F(2,24) = 5.053, P = 0.0147] showed that the maximum effect
of the purine base was achieved in 10 min and decreased after
30 min (Figure 4). The inhibition of ASK1 or PKC by cell pre-
treatment with 10 µM MSC2032964A or 1 µM GF109203X for
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FIGURE 3 | Guanine induces ASK1, p38, JNK, PKC and PKB phosphorylation in SH-SY5Y neuroblastoma cells. SH-SY5Y cells were cultured for 24 h and
incubated for 10 min with 50 µM GUA, in the absence or presence of a cocktail of inhibitors of both nucleoside and nucleobase transmembrane transporters
(100 µM Propentofylline, 10 µM NBTI, 10 µM Dypiridamole). Representative Immunoblot analysis of (A1) p-ASK1 (Thr845), (A2) p-p38, (A3) p-JNK, (B) PKC,
(C) p-PKB, with the respective β-actin as loading control, and the correspondent quantitative data of densitometric analysis. Each column represents the
mean ± SEM of four independent experiments, and it is expressed as relative protein expression normalized to β-actin. Student’s t-test: ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001, vs. untreated cells (Basal); #P < 0.05, ##P < 0.01, vs. GUA-treated cells.
30 min, respectively, did not affect basal ERK phosphorylation,
and only in part reduced that induced by GUA [two-way
ANOVA: GUA effect F(1,16) = 4.543, P < 0.0489, ASK1 inhibitor
effect F(1,16) = 37.66, P < 0.0001 with interaction values between
factors of F(3,32) = 4.449, P = 0.0499; GUA effect F(1,16) = 3.220,
P < 0.0917, PKC inhibitor effect F(1,16) = 39.35, P < 0.0001
with interaction values between factors of F(3,32) = 4.504,
P = 0.0498]. Conversely, the inhibition of PKB by cell pre-
treatment with 10 µM 10-DEBC dihydrochloride, as well as the
inhibition of the upstream PI3K by 25 µM LY294002, did not
modify the basal p-ERK expression and strongly reduced that
elicited by GUA [two-way ANOVA: GUA effect F(1,16) = 10.84,
P < 0.0046, 10-DEBC effect F(1,16) = 22.53, P < 0.0002
with interaction values between factors of F(3,32) = 13.82,
P = 0.0019; GUA effect F(1,16) = 6.456, P < 0.0218, LY294002
effect F(1,16) = 20.12, P < 0.0004 with interaction values
between factors of F(3,32) = 8.564, P = 0.0098] (Figures 5A,B).
This suggests that, in SH-SY5Y cells, PI3-PKB-ERK signaling
cascade is likely the main pathway activated by extracellular
GUA.
GUA Activates PKB-ERK Signaling
Pathway in a Pertussis-Toxin Sensitive
Manner
We, then, inquired whether GUA effect may be ascribed
to an eventual interaction with a new putative receptor.
For this purpose, SH-SY5Y cells were treated for 4 h with
200 ng/mL Pertussis Toxin (PTX), a specific inhibitor of Gi/Go-
proteins, and the expression of p-ERK 1/2 was analyzed by
Immunoblot. PTX did not affect basal ERK1/2 phosphorylation
but significantly reduced that induced by GUA [two-way
ANOVA: F(1,16) = 9.795, P = 0.0065 with interaction values
between factors of F(1,16) = 16.09, P = 0.0010], thus supporting
the involvement of a Gi protein-coupled receptor in the effect of
GUA (Figure 5C).
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FIGURE 4 | Guanine induces ERK1 phosphorylation in SH-SY5Y neuroblastoma cells in a dose-dependent manner. Representative Immunoblot analysis of ERK1/2
expression in SH-SY5Y cells, with β-actin as loading control, and the correspondent quantitative data of densitometric analysis. (A) Cells were cultured for 24 h and
exposed for 10 min to different concentrations of GUA (0–100 µM). (B) The time course of activation of ERK1/2 induced by GUA. Cells were cultured for 24 h and
exposed to 50 µM GUA for different time points (0–30 min). Each column represents the mean ± SEM of at least four independent experiments, and it is expressed
as relative protein expression normalized to β-actin.
Extracellular GUA Stimulates the
PI3K-PKB Phosphorylation and NO
Production and Activates the
Downstream sGC-cGMP-PKG-ERK
Pathway
Nitric oxide (NO) is known to induce ERK phosphorylation
via sGC-cGMP-PKG pathway, (Prickaerts et al., 2001; Suvarna
and O’Donnell, 2002; Boess et al., 2004; Rutten et al., 2007;
Chien et al., 2008; Masood et al., 2009; Xu et al., 2013;
Bollen et al., 2014; Matsumoto et al., 2016). Hence, we
evaluated the involvement of NO system on GUA-induced
ERK phosphorylation, by selectively blocking every step of this
cascade and by analyzing p-ERK1/2 expression by Immunoblot.
As expected, phosphodiesterase inhibitor, 10 µM IBMX,
strongly enhanced GUA-induced ERK phosphorylation [two-
way ANOVA: IBMX effect F(1,16) = 67.23, P < 0.0001].
Most importantly, NOS inhibitor, 1 mM L-NAME, completely
prevented ERK1/2 phosphorylation elicited by GUA [two-way
ANOVA: L-NAME effect F(1,16) = 16.82, P < 0.0008]. The cell
co-treatment with IBMX and L-NAME partially restored GUA-
induced ERK phosphorylation, thus confirming the presence
of other pathways converging on cGMP activation. The sGC
inhibitor, 10 µM ODQ, likewise L-NAME, completely abrogated
GUA-mediated ERK phosphorylation [two-way ANOVA: ODQ
effect F(1,16) = 25.33, P < 0.0001]. Of note, among the possible
pathways involved in the PKB-ERK signaling, extracellular GUA
stimulates the PI3K-PKB phosphorylation and NO production,
thus evoking the downstream activation of sGC-cGMP-PKG
pathway (Figure 6). Corroborating with these findings, PDE
inhibitors have been shown to improve cognitive skills and
memory formation in rodents (Reneerkens et al., 2009). The
mechanism likely involves the induction of cAMP-protein
kinase A (PKA)-cAMP responsive element-binding protein
(CREB) and cGMP-PKG-CREB signaling pathways (Rutten et al.,
2007), which are both associated with late-phase of Long-Term
Potentiation (LTP).
The Activation of the
cAMP-Epac-CaMKII Pathway Influences
NOS Activity
In an attempt to investigate whether the activation of collateral
signaling pathway was able to affect the NO-sGC-cGMP-
PKG-ERK cascade, we examined the possible role of cAMP-
Epac-CaMKII pathway. CaMKII (Ca2+/calmodulin-dependent
protein kinases II) is highly expressed in hippocamapal neurons
and is involved in the glutamate-mediated LTP phase, wherein
two major events occur: (i) Ca2+ enters the cell through NMDA
channels and activates CaMKII that, in turn, recruits AMPA
receptors to the plasma membrane; (ii) Ca2+ increases cAMP
that activates ERK signaling (Giovannini, 2006; Miyamoto,
2006).
It has been recently proposed that extracellular cGMP
regulates the glutamate-NO-cGMP pathway in a learning task,
and this modulation resulted to be biphasic and relied on an
inverse correlation between CaMKII and NOS activity (Moosavi
et al., 2014; Cabrera-Pastor et al., 2016).
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FIGURE 5 | Guanine induces ERK1 phosphorylation in SH-SY5Y neuroblastoma cells via PI3K-PKB-ERK signaling pathway in a PTX-sensitive manner.
Representative Immunoblot analysis of ERK1/2 expression in SH-SY5Y cells, with β-actin as loading control, and the correspondent quantitative data of
densitometric analysis. Cells were cultured for 24 h and exposed for 10 min (A,B) or for 4 h (C) to 50 µM GUA, in the absence or presence of (A) ASK1 inhibitor,
10 µM MSC2032964A, (B) PKC inhibitor (1 µM GF109203X), PKB inhibitor (10 µM 10-DEBC dihydrochloride), PI3K inhibitor (25 µM LY294002), (C) 200 ng/mL
Pertussis Toxin (PTX.) Each column represents the mean ± SEM of at least four independent experiments, and it is expressed as relative protein expression
normalized to β-actin. Student’s t-test: ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, vs. untreated cells (Basal); #P < 0.05, ##P < 0.01, vs. GUA-treated cells, §P < 0.05,
vs. GUA- and GF109203X-treated cells.
In our study, Immunoblot analysis of p-ERK showed that
2,5 µM 8-CPT-cAMP, an EPAC specific cAMP analog, inhibited
GUA-induced ERK phosphorylation [two-way ANOVA: effect of
8-CPT-cAMP F(1,16) = 18.16, P < 0.0006], although this result
has to be further elucidated by using an EPAC-specific inhibitor.
The inhibitor of CaMKII, 20 µM KN-93, caused an opposite
effect and significantly enhanced p-ERK expression [two-way
ANOVA: effect of KN-93 F(1,16) = 30.80, P < 0.0001] (Figure 6).
Therefore, we hypothesized that the functional interplay between
NOS activity and CaMKII phosphorylation, observed in our
experimental model, might have similar features to the above-
mentioned glutamate-NO-cGMP pathway.
GUA Enhances NO Production in
SH-SY5Y Cells and Pre-treatment with
L-NAME Prevents This Effect
Finally, in order to compare the present data with those
previously obtained in vivo (Giuliani et al., 2012), wherein
L-NAME was able to prevent the GUA-mediated mnesic effect,
we evaluated the effects of GUA on NO production. Cell exposure
to 50 µM GUA for 30 min significantly increased NO production
[two-way ANOVA: GUA effect F(1,16) = 6.451, P < 0.0218,
L-NAME effect F(1,16) = 6.451, P < 0.0218 with interaction
values between factors of F(1,16) = 4.681, P = 0.0460] (Figure 7).
A similar effect has been obtained when SH-SY5Y cells were
challenged with 2 µM ionomycin, a calcium ionophore that
induces NO production mainly via mobilization of intracellular
Ca2+ [two-way ANOVA: GUA effect F(1,16) = 5.523, P < 0.0319,
ionomycin effect F(1,16) = 5.523, P < 0.0319 with interaction
values between factors of F(1,16) = 4.190, P = 0.0575]. Cell pre-
treatment (15 min before exposure to GUA or ionomycin) with
5 µM L-NAME, which per se did not affect the NO production of
SH-SY5Y cells, strongly reduced the NO production induced by
either GUA or ionomycin (Figure 7).
DISCUSSION
This work provides new insights on the transduction pathways
involved in neuronal plasticity, in particular on the putative
mechanism responsible of GUA-induced mnesic effects.
The major findings of the present study, performed in a
model of neuronal-like cells (SH-SY5Y cells), are the following:
(i) in resting condition, GUA is present in the intercellular
milieu and derives from GTP breakdown, promoted by the
activity of purine-converting enzymes (i.e., PNP and GDA)
released in the culture medium; (ii) the inhibition of specific
nucleoside and nucleobase transmembrane transporters
enhances the extracellular levels of GUO, GUA and XAN;
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FIGURE 6 | Guanine activates sGC-cGMP-PKG-ERK signaling pathway in SH-SY5Y neuroblastoma cells. Representative Immunoblot analysis of ERK1/2
expression in SH-SY5Y cells, with β-actin as loading control, and the correspondent quantitative data of densitometric analysis. Cells were cultured for 24 h and
exposed for 30 min to 100 µM GUA, 50 µM GUA, a phosphodiesterase inhibitor (10 µM IBMX), a NOS inhibitor (1 mM L-NAME), a sGC inhibitor (10 µM ODQ), an
EPAC specific cAMP analog (2,5 µM 8-CPT-cAMP), a CaMKII inhibitor (20 µM KN-93). Each column represents the mean ± SEM of at least three independent
experiments, and it is expressed as relative protein expression normalized to β-actin. Student’s t-test: ∗∗∗P < 0.001, vs. untreated cells (Basal); #P < 0.05,
###P < 0.001, vs. GUA-treated cells, §P < 0.05, vs. GUA- and L-NAME-treated cells.
(iii) the addition of GUA to the culture medium caused a
non-massive and dose-dependent production of ROS, and
promotes the phosphorylation of ASK1, p38, JNK, PKC
and PKB; (iv) extracellular GUA stimulates the PI3K-PKB
phosphorylation and NO production, and activates the
downstream sGC-cGMP-PKG-ERK pathway in a pertussis-
toxin sensitive manner; (v) GUA-induced NO production
is negatively modulated by the EPAC-cAMP-CAMKII
pathway.
To better understand the results of this study, it has to be
emphasized that, both in vitro and in vivo (Rathbone et al., 2008;
Giuliani et al., 2012), the system of the extracellular guanine-
based purines, together with a physiological and concerted
activity of the enzymes regulating their metabolism (in particular
PNP and GDA), is basically oriented to generate an higher
amount of GUA rather than GUO or XAN; moreover, GUA
stimulates the cGMP formation through NO production, which
is known to modulate a broad range of effects in the CNS,
such as neuronal development and synaptic plasticity (Prast and
Philippu, 2001).
The evidence of the involvement of NO-cGMP pathway in
some forms of learning and memory has been worked out
by many authors (Erceg et al., 2005; Piedrafita et al., 2007;
Ben Aissa et al., 2016; Cabrera-Pastor et al., 2016; Zhou et al.,
2017). In several brain areas (i.e., hippocampus, cerebellum
and striatum), increased levels of cGMP seemed to improve
learning and memory consolidation, mainly during early stages
of memory formation (immediately after training). This data is
confirmed by full amnesia for inhibitory avoidance task when
rats were treated with LY 83583, a soluble guanylate cyclase
inhibitor, immediately after training (Bernabeu et al., 1997).
However, not all signal transduction pathways, leading to cGMP
formation, cause beneficial effects on cognitive functions. For
example, cGMP has been found to mediate the stimulation
of dendritic number and branching as well as the neurite
elongation. This event likely occurs as a consequence of an
interplay between cGMP and the activity of extrinsic/external
factors such as neurotrophins (Tian et al., 2017) that, usually,
stimulate cAMP formation. Cyclic nucleotides are differently
involved in the memory consolidation process, since it has
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FIGURE 7 | Guanine increases NO production in SH-SY5Y neuroblastoma
cells. SH-SY5Y cells were treated for 30 min with 5 µM L-NAME or 50 µM
GUA (alone or in combination), 2 µM ionomycin (ION), alone or in combination
with 5 µM L-NAME. NOS activity was determined by the conversion of
L-[3H]-arginine into L-[3H]-citrulline and expressed as pmol/NO/min/mg prot
tot. Data were expressed as means ± SEM of four different experiments.
Student’s t-test: ∗P < 0.05, ∗∗P < 0.01, vs. untreated cells (Basal); #P < 0.05,
vs. GUA-treated cells.
been reported that cGMP regulates the early consolidation
phase, whereas cAMP is implicated in late processes of memory
formation (Izquierdo et al., 2006; Rutten et al., 2007; Bollen
et al., 2014). In this functional interplay, a significant role seems
to be played by the guanine-based purines, in particular by
GUO and GUA. Indeed, several studies reported that GUO
causes memory impairment (Roesler et al., 2000; Vinadé et al.,
2003, 2004) but, at the same time and sinergistically with NGF,
it promotes neurite outgrowth in PC12 cells via activation of
heme-oxygenase and cGMP formation (Gysbers and Rathbone,
1996; Bau et al., 2005; Tomaselli et al., 2005). Cell exposure to
neurotrophic factors such as NGF, for more than 24 h, promotes
the phosphorylation of PKC-Ras-MAPK (Kumar et al., 2005)
and, in turn, increases the mRNA levels of GDA, responsible
of GUA degradation (Rathbone et al., 1999). This enzyme
favors dendrite branching and elongation by directly binding
tubulin heterodimers, thus promoting the microtubule assembly
via cytoskeletal rearrangement (Akum et al., 2004). Therefore,
the synergistic activity of neurotrophins with agents promoting
neuritogenesis, such as GUO, explains why the neurogenic
activity of GUO, despite being linked to an increased cGMP
formation, is associated with an amnesic effect. Conversely, GUA
promotes the early stages of memory formation in rats (Giuliani
et al., 2012) and its effect seems to be linked to the NO-cGMP
signaling pathway. In line with it, we observed that L-NAME
prevented memory consolidation caused by the administration of
GUA in vivo, in a model of passive avoidance task (Giuliani et al.,
2012). In the same study, the administration of GUA, 15 min
before treatment with L-NAME, prevented the amnesic effect of
the NOS inhibitor.
The involvement of the NO-cGMP-PKG-ERK signaling
pathway in synaptic plasticity has been extensively reported
(Chien et al., 2008; Ota et al., 2010; Bartus et al., 2013;
Matsumoto et al., 2016). However, the role of NO in each step
of learning appears controversial and it might be task-dependent.
ERK cascade is positively implicated in the development of
fear conditioning, conditioned taste aversion memory, spatial
memory, step-down inhibitory avoidance and object recognition
memory (Giovannini, 2006; Chen et al., 2017; Vithayathil et al.,
2017). In our study, this pathway resulted to be activated
upon cell exposure to GUA. Specifically, extracellular GUA
stimulated the PI3K-PKB phosphorylation and NO production,
and activated the downstream sGC-cGMP-PKG-ERK pathway.
It is feasible that GUA-induced ROS production, with the
subsequent phosphorylation of ASK1, p38 and JNK, may
contribute to the cGMP formation trough other pathways than
NO, as confirmed by our data, wherein, in cells pre-treated with
L-NAME, the inhibition of phosphodiesterases caused a limited
increase in GUA-induced ERK1/2 phosphorylation.
Noteworthy, if the role of cGMP in learning and memory
is important, much more valuable is that its mnesic effect
is mediated by NO production. Indeed, the increase of the
intracellular levels of cGMP induced by GUO, through the
activation of HEME-oxygenase and independent of the NO
production, is important for the dendrite and neurite outgrowth
but it is associated with amnesia (Vinadé et al., 2004; Bau et al.,
2005).
We, then, took into account the existence of a more
complex network, wherein the NO production is eventually
under the control of other molecular mechanisms and, among
them, we investigated the EPAC-CAMKII system. CaMKII has
a prominent role in memory formation (LTM) (Tan, 2007;
Takao et al., 2010; Giese and Mizuno, 2013; Nakamura et al.,
2017). For this purpose, we took advantage of a recent study,
where they showed that the activation of CAMKII, upon
stimulation of NMDA receptors, inhibits the production of
NO that functions as a retrograde signal able to modulate the
glutamatergic system (Cabrera-Pastor et al., 2016). Noteworthy,
in our model, the activity of GUA was similar to that of glutamate,
since we observed that the stimulation of the EPAC-CAMKII
pathway inhibited the NO-mediated phosphorylation of ERK1/2
induced by GUA. The blockage of this pathway by using a
CaMKII inhibitor, KN-93, amplified GUA effect. Consistent
with it, two endogenous CaMKII inhibitors (CaMK2N1 and
CaMK2N2) have been shown to prevent memory loss after
retrieval (Vigil et al., 2017). However, it should be pointed out
that the influence exerted by CaMKII on the phosphorylation
of ERK is not univocal. Indeed, it has been reported that:
(i) in vascular smooth muscle cells the CaMKII inhibitor KN-93
caused an H2O2-mediated reduction of ERK1/2 and PKB
phosphorylation (Robison et al., 2007; Bouallegue et al., 2009);
(ii) the presynaptic injection of a CaMKII inhibitor blocked LTP
and neurotransmitter release induced by either the NO donor or
the PKG activator (Feil and Kleppisch, 2008).
Finally, we speculated that the extracellular effect of GUA
may be mediated by a membrane receptor at present not well
identified. In this study, cell treatment with pertussis toxin
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strongly reduced the GUA-evoked ERK1/2 phosphorylation, thus
indicating that this putative new GUA receptor is likely coupled
with Gi/o proteins.
Guanine-based purines, in particular GUO, seems to bind to
metabotropic receptors and many of their effects are mediated
through G-protein-dependent signaling pathways; it has been
shown, for instance, that the pertussis toxin-mediated inhibition
of Gi/Go-protein reverses some of the effects of GUO on cell
viability and glutamate uptake in hippocampal slices (Traversa
et al., 2003; Dal-Cim et al., 2012, 2013).
Several years ago, our group found a specific [3H]-guanosine
binding site in rat brain membranes, compatible with an
unknown G protein-coupled receptor (Traversa et al., 2002, 2003;
Di Liberto et al., 2012; Grillo et al., 2012). In order to provide
insight into the characteristics of the binding site, we evaluated
the relative abilities of purine analogs to displace [3H]GUO.
Binding data revealed that all the adenine-based purines as well
as GTP, GDP and GMP were ineffective in displacing [3H]GUO.
The 6-Thio-GUO or 6-keto-GUO derivatives resulted to be as
effective as GUO in displacing [3H]GUO. On the contrary, the
binding affinity was strongly reduced when the 6-amino or 2-
amino derivatives were assayed.
These findings seem to be compatible with a membrane
binding site, expressed in the rat brain, which, in addition to
GUO, may interact with GUA, although with a lower affinity.
At present, we are carrying out a study to individuate and
functionally characterize this new putative receptor.
At the same time, it cannot be excluded an interaction of GUA
with another receptor functionally different from G protein-
coupled receptors. Indeed, it is well known that compounds that
are structurally very similar to GUO and GUA represent the main
agonists of several Toll-like receptors (i.e., TLR9, 7 and 8) (Lee
et al., 2003; Yu et al., 2017).
In this context, it has been recently reported that the
stimulation of some subtypes of Toll-Like receptors (TLR9,
7 and 8) in microglial cells leads to cognitive improvements
and ameliorates the vascular amyloid pathology in triple
transgenic mice expressing human Swedish K670N/M671L
and vasculotropic Dutch/Iowa E693Q/D694N mutations and
exhibiting early cerebral microvascular accumulation of Aβ
(Scholtzova et al., 2017). Interestingly, some guanine-based
purines and their modified derivatives have been recently
recognized as endogenous ligands for TLRs, especially 7 and 9
subtypes (Shibata et al., 2016; Abdul-Cader et al., 2017). In this
regard, in order to eliminate the effects potentially mediated by
TLRs, in our study we used cultured SH-SY5Y cells, wherein the
expression of TLR 7/8 and 9 is not reported in literature.
CONCLUSION
Targeting NO-cGMP-PKG-ERK signaling pathway may
represent an interesting approach for the development of new
drugs in the treatment of memory dysfunctions occurring
in neurodegenerative and psychiatric diseases, among others
Alzheimer’s disease and dementia. Initial promising findings
in this direction have been reported regarding the use of PDE
inhibitors (Kumar and Singh, 2017; Prickaerts et al., 2017)
or sGC stimulator (Montfort et al., 2017) in the treatment of
neuroinflammatory and neuropathological conditions.
It is plausible to expect that, beyond the above-mentioned
guanine-derivatives, the administration of GUA itself (Giuliani
et al., 2012), due to its long half-life in vivo, may elicit
molecular changes that underlie synaptic alterations and memory
formation through a putative receptor that could represent a
new pharmacological target. This may serve the purpose of
avoiding a major challenge, that is to discriminate the numerous
downstream effectors ensuing the activation of NO-cGMP-ERK
signaling pathway, thus bypassing the sophisticated network of
different and multifunctional protein kinases.
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